Register Login

SILEXION THERAPEUTICS CORP (SLXN)

SymbolSLXN
NameSILEXION THERAPEUTICS CORP
SectorHEALTH CARE
RegionMiddle East
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
Address12 ABBA HILLEL ROAD, RAMAT-GAN, Illinois, 5250606, United States
Telephone+972 3 - 756-4999
Fax—
Email—
Websitehttps://silexion.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0002022416
Description

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Additional info from NASDAQ:
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

2026-08-14 17:32

New Form PRE 14A - Silexion Therapeutics Corp <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001178913-26-004145 <b>Size:</b> 254 KB

Read more
2026-08-14 12:45

Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Read more
2026-08-13 21:06

(75% Positive) SILEXION THERAPEUTICS CORP (SLXN) Files Form 8-K

Read more
2026-08-13 20:02

(70% Positive) SILEXION THERAPEUTICS CORP (SLXN) Provides Update on agent for general corporate purposes

Read more
2026-08-13 12:01

New Form 424B4 - Silexion Therapeutics Corp <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0001178913-26-004116 <b>Size:</b> 3 MB

Read more
2026-08-12 07:04

New Form EFFECT - Silexion Therapeutics Corp <b>Filed:</b> 2026-08-11 <b>AccNo:</b> 9999999995-26-002627 <b>Size:</b> 1 KB

Read more
2026-08-10 10:16

(90% Positive) SILEXION THERAPEUTICS CORP (SLXN) Files Form 8-K

Read more
2026-08-07 17:38

New Form S-1 - Silexion Therapeutics Corp <b>Filed:</b> 2026-08-07 <b>AccNo:</b> 0001178913-26-003961 <b>Size:</b> 3 MB

Read more
2026-08-04 13:15

Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers

Read more
2026-07-29 20:05

(90% Positive) SILEXION THERAPEUTICS CORP (SLXN) Provides Update on commence for KRAS-driven cancers

Read more